John A Baron1, Elizabeth L Barry, Leila A Mott, Judy R Rees, Robert S Sandler, Dale C Snover, Roberd M Bostick, Anastasia Ivanova, Bernard F Cole, Dennis J Ahnen, Gerald J Beck, Robert S Bresalier, Carol A Burke, Timothy R Church, Marcia Cruz-Correa, Jane C Figueiredo, Michael Goodman, Adam S Kim, Douglas J Robertson, Richard Rothstein, Aasma Shaukat, March E Seabrook, Robert W Summers. 1. From the Departments of Medicine (J.A.B., D.J.R., R.R.) and Epidemiology (J.A.B., E.L.B., L.A.M., J.R.R.), Geisel School of Medicine at Dartmouth, Hanover, and Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon (D.J.R., R.R.) - both in New Hampshire; the Departments of Medicine (J.A.B., R.S.S.) and Biostatistics (A.I.), University of North Carolina at Chapel Hill, Chapel Hill; the Department of Pathology, Fairview Southdale Hospital, Edina (D.C.S.), and the Division of Environmental Health Sciences, University of Minnesota School of Public Health (T.R.C.), Minnesota Gastroenterology (A.S.K.), Department of Medicine, University of Minnesota (A.S.), and Minneapolis Veterans Affairs (VA) Medical Center (A.S.), Minneapolis - all in Minnesota; the Department of Epidemiology, Rollins School of Public Health, Emory University and Winship Cancer Institute, Emory University, Atlanta (R.M.B., M.G.); the Department of Mathematics and Statistics, University of Vermont, Burlington (B.F.C.), and VA Outcomes Group, White River Junction (D.J.R.) - both in Vermont; the Department of Medicine, University of Colorado School of Medicine, Denver (D.J.A.); the Departments of Quantitative Health Sciences (G.J.B.) and Gastroenterology and Hepatology (C.A.B.), Cleveland Clinic, Cleveland; the Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M.D. Anderson Cancer Center, Houston (R.S.B.); Puerto Rico Cancer Center, Medical Sciences Campus, University of Puerto Rico, San Juan (M.C.-C.); the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (J.C.F.); Consultants in Gastroenterology, West Columbia, SC (M.E.S.); and the Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City (R.W.S.).
Abstract
BACKGROUND: Epidemiologic and preclinical data suggest that higher intake and serum levels of vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To further study the chemopreventive potential of these nutrients, we conducted a randomized, double-blind, placebo-controlled trial of supplementation with vitamin D, calcium, or both for the prevention of colorectal adenomas. METHODS: We recruited patients with recently diagnosed adenomas and no known colorectal polyps remaining after complete colonoscopy. We randomly assigned 2259 participants to receivedaily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both, or neither in a partial 2×2 factorial design. Women could elect to receive calcium plus random assignment to vitamin D or placebo. Follow-up colonoscopy was anticipated to be performed 3 or 5 years after the baseline examinations, according to the endoscopist's recommendation. The primary end point was adenomas diagnosed in the interval from randomization through the anticipated surveillance colonoscopy. RESULTS: Participants who were randomly assigned to receive vitamin D had a mean net increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relative to participants given placebo. Overall, 43% of participants had one or more adenomas diagnosed during follow-up. The adjusted risk ratios for recurrent adenomas were 0.99 (95% confidence interval [CI], 0.89 to 1.09) with vitamin D versus no vitamin D, 0.95 (95% CI, 0.85 to 1.06) with calcium versus no calcium, and 0.93 (95% CI, 0.80 to 1.08) with both agents versus neither agent. The findings for advanced adenomas were similar. There were few serious adverse events. CONCLUSIONS: Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after removal of colorectal adenomas did not significantly reduce the risk of recurrent colorectal adenomas over a period of 3 to 5 years. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00153816.).
RCT Entities:
BACKGROUND: Epidemiologic and preclinical data suggest that higher intake and serum levels of vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To further study the chemopreventive potential of these nutrients, we conducted a randomized, double-blind, placebo-controlled trial of supplementation with vitamin D, calcium, or both for the prevention of colorectal adenomas. METHODS: We recruited patients with recently diagnosed adenomas and no known colorectal polyps remaining after complete colonoscopy. We randomly assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both, or neither in a partial 2×2 factorial design. Women could elect to receive calcium plus random assignment to vitamin D or placebo. Follow-up colonoscopy was anticipated to be performed 3 or 5 years after the baseline examinations, according to the endoscopist's recommendation. The primary end point was adenomas diagnosed in the interval from randomization through the anticipated surveillance colonoscopy. RESULTS:Participants who were randomly assigned to receive vitamin D had a mean net increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relative to participants given placebo. Overall, 43% of participants had one or more adenomas diagnosed during follow-up. The adjusted risk ratios for recurrent adenomas were 0.99 (95% confidence interval [CI], 0.89 to 1.09) with vitamin D versus no vitamin D, 0.95 (95% CI, 0.85 to 1.06) with calcium versus no calcium, and 0.93 (95% CI, 0.80 to 1.08) with both agents versus neither agent. The findings for advanced adenomas were similar. There were few serious adverse events. CONCLUSIONS: Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after removal of colorectal adenomas did not significantly reduce the risk of recurrent colorectal adenomas over a period of 3 to 5 years. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00153816.).
Authors: David Z J Chu; Michael A Hussey; David S Alberts; Frank L Meyskens; Cecilia M Fenoglio-Preiser; Saul E Rivkin; Glenn M Mills; Jeffrey K Giguere; Charles D Blanke; Gary E Goodman Journal: Clin Colorectal Cancer Date: 2011-07-22 Impact factor: 4.481
Authors: Stephanie J Weinstein; Kai Yu; Ronald L Horst; Jason Ashby; Jarmo Virtamo; Demetrius Albanes Journal: Am J Epidemiol Date: 2011-01-19 Impact factor: 4.897
Authors: J A Baron; M Beach; J S Mandel; R U van Stolk; R W Haile; R S Sandler; R Rothstein; R W Summers; D C Snover; G J Beck; J H Bond; E R Greenberg Journal: N Engl J Med Date: 1999-01-14 Impact factor: 91.245
Authors: Joan M Lappe; Dianne Travers-Gustafson; K Michael Davies; Robert R Recker; Robert P Heaney Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Elizabeth L Barry; Leila A Mott; Michal L Melamed; Judith R Rees; Anastasia Ivanova; Robert S Sandler; Dennis J Ahnen; Robert S Bresalier; Robert W Summers; Roberd M Bostick; John A Baron Journal: PLoS One Date: 2014-10-15 Impact factor: 3.240
Authors: NaNa Keum; Li Liu; Tsuyoshi Hamada; Zhi Rong Qian; Jonathan A Nowak; Yin Cao; Annacarolina da Silva; Keisuke Kosumi; Mingyang Song; Daniel Nevo; Molin Wang; Andrew T Chan; Jeffrey A Meyerhardt; Charles S Fuchs; Kana Wu; Shuji Ogino; Reiko Nishihara; Xuehong Zhang Journal: Cancer Causes Control Date: 2019-04-08 Impact factor: 2.506
Authors: Hannah B Mandle; Ferdous A Jahan; Roberd M Bostick; John A Baron; Elizabeth L Barry; Rami Yacoub; Julia Merrill; Robin E Rutherford; March E Seabrook; Veronika Fedirko Journal: Mol Carcinog Date: 2019-04-02 Impact factor: 4.784
Authors: Elizabeth L Barry; Jennifer L Lund; Daniel Westreich; Leila A Mott; Dennis J Ahnen; Gerald J Beck; Roberd M Bostick; Robert S Bresalier; Carol A Burke; Timothy R Church; Judy R Rees; Douglas J Robertson; John A Baron Journal: Int J Cancer Date: 2018-10-30 Impact factor: 7.396
Authors: Christoph Amadeus Agten; Lukas Margaroli; Susanne Bensler; Benjamin Fritz; Andrea B Rosskopf; Ulrike Held; Christian W A Pfirrmann Journal: Skeletal Radiol Date: 2018-02-02 Impact factor: 2.199
Authors: Audrey H Calderwood; John A Baron; Leila A Mott; Dennis J Ahnen; Roberd M Bostick; Jane C Figueiredo; Michael N Passarelli; Judy R Rees; Douglas J Robertson; Elizabeth L Barry Journal: Cancer Prev Res (Phila) Date: 2019-03-04
Authors: Xuehong Zhang; NaNa Keum; Kana Wu; Stephanie A Smith-Warner; Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci Journal: Int J Cancer Date: 2016-08-09 Impact factor: 7.396